Payment overview · 2025
General Payments
$336.10
16 reported records · 7 companies
Healthcare provider profile · identity verified
Ronald W Kennett, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · GOODYEAR, AZ · NPI 1154318996
Verified facts
What the public records show
CMS Open Payments records show Ronald W Kennett, D.O. received $336.10 in general payments during 2025 across 16 reported records.
GlaxoSmithKline, LLC. accounted for 31.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $106.20 | 31.6% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $82.47 | 24.5% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$39.89 | 11.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.87 | 8.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $27.81 | 8.3% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $25.71 | 7.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $25.15 | 7.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $336.10 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $106.20 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.74 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $33.73 | 2 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $28.87 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $28.87 | 1 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $28.87 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.81 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $27.81 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $25.71 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $25.15 | 1 | 2025 |
Source payment records
|
|||||
| SYNCHROMEDII Normalized: synchromedii |
Device | Medtronic, Inc. | $22.88 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 795 | 230 |
| Levothyroxine Sodium | Levothyroxine Sodium | 399 | 108 |
| Metformin Hcl | Metformin Hcl | 366 | 105 |
| Lisinopril | Lisinopril | 365 | 104 |
| Amlodipine Besylate | Amlodipine Besylate | 278 | 86 |
| Losartan Potassium | Losartan Potassium | 270 | 83 |
| Pantoprazole Sodium | Pantoprazole Sodium | 267 | 80 |
| Pioglitazone Hcl | Pioglitazone Hcl | 237 | 70 |
| Gabapentin | Gabapentin | 208 | 70 |
| Omeprazole | Omeprazole | 192 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 190 | 65 |
| Simvastatin | Simvastatin | 181 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 170 | 55 |
| Tramadol Hcl | Tramadol Hcl | 170 | 48 |
| Pravastatin Sodium | Pravastatin Sodium | 164 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 148 | 50 |
| Furosemide | Furosemide | 147 | 64 |
| Trazodone Hcl | Trazodone Hcl | 132 | 49 |
| Alprazolam | Alprazolam | 115 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 115 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 108 | 36 |
| Lovastatin | Lovastatin | 94 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 94 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 26 |
| Famotidine | Famotidine | 89 | 30 |
| Prednisone | Prednisone | 88 | 65 |
| Alendronate Sodium | Alendronate Sodium | 87 | 22 |
| Buspirone Hcl | Buspirone Hcl | 86 | 29 |
| Montelukast Sodium | Montelukast Sodium | 80 | 23 |
| Atenolol | Atenolol | 78 | 23 |
| Farxiga | Dapagliflozin Propanediol | 77 | 19 |
| Carvedilol | Carvedilol | 74 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | 19 |
| Meloxicam | Meloxicam | 74 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 73 | suppressed |
| Januvia | Sitagliptin Phosphate | 72 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 22 |
| Allopurinol | Allopurinol | 67 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 64 | 11 |
| Lorazepam | Lorazepam | 62 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 32 |
| Potassium Chloride | Potassium Chloride | 60 | 21 |
| Sertraline Hcl | Sertraline Hcl | 59 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 20 |
| Fenofibrate | Fenofibrate | 53 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 28 |
| Oxybutynin Chloride | Oxybutynin Chloride | 51 | 21 |
| Meclizine Hcl | Meclizine Hcl | 49 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 15 |
| Azithromycin | Azithromycin | 47 | 41 |
| Ibuprofen | Ibuprofen | 43 | 17 |
| Eliquis | Apixaban | 38 | 11 |
| Ozempic | Semaglutide | 38 | suppressed |
| Jardiance | Empagliflozin | 37 | 14 |
| Ondansetron Odt | Ondansetron | 37 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 14 |
| Ezetimibe | Ezetimibe | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 34 | 17 |
| Celecoxib | Celecoxib | 33 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | 12 |
| Finasteride | Finasteride | 31 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 26 |
| Rybelsus | Semaglutide | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Nifedipine Er | Nifedipine | 25 | 11 |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 21 |
| Naproxen | Naproxen | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | 14 |
| Trulicity | Dulaglutide | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Methadone Hcl | Methadone Hcl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Nateglinide | Nateglinide | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Captopril | Captopril | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $336.10 · 16 records | GlaxoSmithKline, LLC. | AVYCAZ, DALVANCE, INTELLIS ADAPTIVESTIM, Korlym, Leqembi, MOUNJARO, Ozempic, SYNCHROMEDII, TEFLARO, TRELEGY ELLIPTA, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error